RIC in COVID-19—a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19.

Autor: Davidson, Sean M., Lukhna, Kishal, Gorog, Diana A., Salama, Alan D., Castillo, Alejandro Rosell, Giesz, Sara, Golforoush, Pelin, Kalkhoran, Siavash Beikoghli, Lecour, Sandrine, Imamdin, Aqeela, do Carmo, Helison R. P., Bovi, Ticiane Gonçalez, Perroud Jr, Mauricio W., Ntsekhe, Mpiko, Sposito, Andrei C., Yellon, Derek M.
Zdroj: Cardiovascular Drugs & Therapy; Oct2022, Vol. 36 Issue 5, p925-930, 6p
Abstrakt: Purpose: Coronavirus disease 19 (COVID-19) has, to date, been diagnosed in over 130 million persons worldwide and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several variants of concern have emerged including those in the United Kingdom, South Africa, and Brazil. SARS-CoV-2 can cause a dysregulated inflammatory response known as a cytokine storm, which can progress rapidly to acute respiratory distress syndrome (ARDS), multi-organ failure, and death. Suppressing these cytokine elevations may be key to improving outcomes. Remote ischemic conditioning (RIC) is a simple, non-invasive procedure whereby a blood pressure cuff is inflated and deflated on the upper arm for several cycles. "RIC in COVID-19" is a pilot, multi-center, randomized clinical trial, designed to ascertain whether RIC suppresses inflammatory cytokine production. Methods: A minimum of 55 adult patients with diagnosed COVID-19, but not of critical status, will be enrolled from centers in the United Kingdom, Brazil, and South Africa. RIC will be administered daily for up to 15 days. The primary outcome is the level of inflammatory cytokines that are involved in the cytokine storm that can occur following SARS-CoV-2 infection. The secondary endpoint is the time between admission and until intensive care admission or death. The in vitro cytotoxicity of patient blood will also be assessed using primary human cardiac endothelial cells. Conclusions: The results of this pilot study will provide initial evidence on the ability of RIC to suppress the production of inflammatory cytokines in the setting of COVID-19. Trial Registration: NCT04699227, registered January 7th, 2021. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: